Hemophilia treatment market size was valued at $12.8 billion in 2021, and is estimated to reach $26.9 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031. Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. In severe cases of hemophilia, continuous bleeding occurs after minor trauma or even when there is no obvious injury. Serious complications in the joints, muscles, brain, or other internal organs can result from bleeding. Milder forms of hemophilia do not necessarily involve spontaneous bleeding, and the condition may not become apparent until abnormal bleeding occurs following surgery or a serious injury. The primary treatment for severe hemophilia involves replacing the clotting factor needed through a tube in a vein.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols S.A., Swedish Orphan Biovitrium AB
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/301
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
Coronavirus (COVID-19) was discovered in late December 2019 in Hubei province of Wuhan city in China. The situation of COVID-19 has varied outcome when related to vaccinations. There is an emerging gap in the economic recovery between high-income and low and middle income countries. After the pandemic severely disrupted global trade, the world is witnessing a robust rebound, which helped with the recovery in 2021. Trade contributes to speeding up economic recovery from the pandemic by providing sustained foreign demand for exports and ensuring the availability of imported intermediate products and services. Amidst the initial outbreak of COVID-19, the outlook for the hemophilia treatment industry was negatively impacted by the COVID-19 pandemic. It was thought that hemophilia patients were more prone to COVID-19, which made them more precautious and subjected to avoid the hospitals visits in early 2020. This led to decrease in the use of hemophilia medicines. Moreover, the supply chain of the medicines was also disturbed, which led to increase in demand and supply gap.
In addition, manufacturers were also made to slow down the manufacturing procedure due to the limitations on the numbers of workers allowed. However, the situation of reduced usage of hemophilia medicines is observed to be changing in the 2021 and is expected to totally increase the supply and demand in the near future post pandemic. Overall, the COVID-19 pandemic had a negative impact on the hemophilia treatment market sizeย owing to the various stringent government restrictions for reducing hospital visits. The manufacturers were also hit by the pandemic effect with decrease in demand for hemophilia medicines.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/301
On the basis of type, the hemophilia treatment market is categorized as hemophilia A and hemophilia B. The hemophilia A segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to the rise in incidence of hemophilia A and increased use of factor VIII. Hemophilia A is also projected to exhibit the fastest market growth during the forecast period, owing to technological advancements in treatment of hemophilia and product approval by regulating authorities.
On the basis of drug therapy, the recombinant coagulation factor concentrates therapy segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to increase in the number of recombinant technology products available for the treatment. Moreover, non-factor replacement therapy is projected to exhibit the fastest growth during hemophilia treatment market forecast period, owing to increase in target population and rise in R&D activities on the treatment therapies.
Europe was the highest revenue contributor in the 2021 and is expected to continue the same during the forecast period. This was attributed to the research activities for hemophilia treatment, which are soaring in Europe, owing to the well-established healthcare facilities, recent technological advancements, and rise in demand for early diagnosis of hemophilia due to increase in awareness regarding the disease. Asia-Pacific is projected to register the highest CAGR of 8.3% during the forecast period to the hemophilia treatment market share, owing to increase in incidence of population suffering from hemophilia. In addition, increase in healthcare expenditure offers a lucrative opportunity for the hemophilia treatment industryย growth.
About Us:
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.